Increased systemic availability of albendazole when taken with a fatty meal
- 153 Downloads
We have studied the systemic availability of oral albendazole in 6 patients with echinococcosis either fasting or with breakfast. Albendazole sulphoxide, the pharmacologically active principle, was assayed by HPLC.
Mean plasma concentrations and AUCs were 4.5 times higher when albendazole was given with breakfast than when administered in the fasting state.
We conclude that therapy of echinococcosis with albendazole requires the drug to be taken with meals and that administration on an empty stomach might be more appropriate when intraluminal effects are desired, e.g. for intestinal parasites.
Key wordsalbendazole echinococcosis bioavailability food intake fatty meal
Unable to display preview. Download preview PDF.
- 1.Bircher J, Luder PJ, Schröder R, Robotti G, Meister F (1984) Echinokokkose heute — Morgenröte am Himmel einer medikamentösen Behandlung. Ther Umsch 41: 660–666Google Scholar
- 2.Dawson M, Watson TR (1985) The effect of dose form on the bioavailability of mebendazole in man. Br J Clin Pharmacol 19: 87–90Google Scholar
- 3.Gazder AJ, Roy J (1987) Albendazole suspension in the treatment of intestinal helminthiasis in children. Curr Ther Res 41: 324–327Google Scholar
- 4.McLean A, McNamara PJ, du Souich P, Gibaldi M, Lalka D (1978) Food, splanchnic blood flow, and bioavailability of drugs subject to first pass metabolism. Clin Pharmacol Ther 24: 5–10Google Scholar
- 5.Marriner SE, Morris DL, Dickson B, Bogan JA (1986) Pharmacokinetics of albendazole in man. Eur J Clin Pharmacol 30: 705–708Google Scholar
- 6.Morris DL, Dykes PW, Dickson B, Marriner SE, Bogan JA, Burrows FGO (1983) Albendazole in hydatid disease. Br Med J 286: 103–104Google Scholar
- 7.Muenst GJ, Karlangis G, Bircher J (1980) Plasma concentrations of mebendazole during treatment of echinococcosis. Eur J Clin Pharmacol 17: 375–378Google Scholar
- 8.Welling PG (1977) Influence of food and diet on gastrointestinal drug absorption: A review. J Pharmacokinet Biopharm 5: 291–334Google Scholar